Signing of a large investment (approx. CHF 40M) in a Series B financing in connection with a therapeutic company treating fibrotic disease.

Jacquemoud Stanislas represented the lead investor, which is a US based venture capital fund. 

The team included Philippe Jacquemoud and Aurélie Guex-Crosier.